Background: The breast cancer-screening program is defined as including women between 50 and 69 years old and aims to detect breast cancer in its early stages, which improves the survival outcome. The aim of this study is to explore the differences between female cancer patients at ages between 50 and 69 years old and those older than 69 years regarding the initial tumor stage, method of tumor detection, and conducted oncological treatment.
Methods: Between January 2017 and August 2020, we recruited all breast cancer female patients older than 69 years old who were diagnosed with breast cancer and planned to receive radiotherapy. A similar sample size of female patients between 50 and 69 years old, who were presented to receive radiotherapy at the defined time of the study, was used as a reference group to be compared with the study group.
Results: We identified 132 female patients older than 69 years with breast cancer, who were presented in our department to receive radiotherapy. The control group was represented by 131 female patients at the ages between 50 and 69 years old. The most common stage detected at the time of diagnosis in both groups was stage IA which represented 29% of the study group and 41% of the controlled group. The incidence of Stage IV is significantly higher in the study group (9%) in comparison to the control group (0.8%).
Conclusion: Stage IA is the most common tumor stage detected among female patients older than 69 years as well as those involved in the breast cancer-screening program. The incidence of metastatic disease is significantly higher among patients not involved in the screening program.
Full text article
United Nations Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022: Summary of Results. UN DESA/POP/2022/TR/NO. 3.
Li CH, Haider S, Boutros PC. Age influences on the molecular presentation of tumours. Nat Commun. 2022;11;13(1):208. doi: 10.1038/s41467-021-27889-y.
Hübner J, Katalinic A, Waldmann A, Kraywinkel K. Long-term Incidence and Mortality Trends for Breast Cancer in Germany. Geburtshilfe Frauenheilkd. 2020;80(6):611-618. doi: 10.1055/a-1160-5569.
Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, et al. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. Eur J Cancer. 2018;99:1-8. doi: 10.1016/j.ejca.2018.04.009.
Grimm LJ, Avery CS, Hendrick E, Baker JA. Benefits and Risks of Mammography Screening in Women Ages 40 to 49 Years. Journal of Primary Care & Community Health. 2022;13. doi: 10.1177/21501327211058322.
Siu AL. on behalf of the U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 164(4):279-96, 2016.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
Jahresbericht Evaluation 2020. Deutsches Mammographie-Screening-Programm. Kooperationsgemeinschaft Mammographie, Berlin, Dezember 2022
Peintinger F. National Breast Screening Programs across Europe. Breast Care. 2019;14:354-358. doi: 10.1159/000503715.
Savaridas SL, Gierlinski M, Warwick VR, Evans AE. Opting into breast screening over the age of 70 years: seeking evidence to support informed choice. Clin Radiol. 2022 Sep;77(9):666-672. doi: 10.1016/j.crad.2022.01.057.
Mahase E. Trial to extend breast cancer screening won’t resume randomisation after pandemic. BMJ. 2020; 370:m3337 doi:10.1136/bmj.m3337.
Copyright (c) 2023 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.